Search the Newsreel

Theravance Biopharma (TBPH) Stock Caught Between Fading Gains And Royalty Doubts

Theravance Biopharma (TBPH) reported a significant shift from profit to loss in Q2 2026, with revenue declining by 20.9% year-over-year. The company's earnings per share also moved into negative territory, raising doubts about its reliance on lumpy royalty income and past one-off gains. Both …

Will COSCIENS Biopharma Inc. (CSCI) Beat Estimates Again in Its Next Earnings Report?

Goldman Sachs Sticks to Its Buy Rating for Conocophillips (COP)

Lyell Immunopharma (LYEL) Slides 4.77% to $14.17 as Biotech Risk Appetite Fades - Wave Equality

QNTM Q4 2025 Earnings: Net Loss of $0.71 Per Share, Shares Slide 1.97 - Analyst Earnings Estimate

ABVC BioPharma (ABVC) Financials 2026 - Income Statement and Balance Sheet

Arbutus Biopharma (ABUS) Earnings Date and Reports 2026

Sutro Biopharma (STRO) Earnings Date and Reports 2026 $STRO

The Top 5 Analyst Questions From ConocoPhillips’s Q2 Earnings Call

ConocoPhillips (COP) PT Raised to $153 at UBS

UBS analyst Josh Silverstein has increased the price target for ConocoPhillips (NYSE: COP) to $153.00 from $143.00. The firm is maintaining a Buy rating on the stock. This update is part of a premium article on StreetInsider.com.

What's Going On With COSCIENS Biopharma Inc. Stock Tuesday?

Lyell Immunopharma COO Stephen J. Hill Sells Shares to Cover Tax Withholding on RSU Settlement

Stephen J. Hill, the Chief Operating Officer of Lyell Immunopharma, Inc., conducted an automatic share sale on August 10, 2026. This transaction was carried out to cover tax obligations stemming from the settlement of his vested restricted stock units. The sale was reported in …

COSCIENS Biopharma Swings to First-Half Profit and Cuts Costs as It Exits SEC Reporting

Mereo BioPharma Group Releases Q2 2026 Financial Results

Mereo BioPharma Group plc reported a narrower loss for the second quarter of 2026, with a loss per share of $0.01 compared to $0.02 in the prior year, despite recording no revenue. The company achieved a net loss of $7.0M, attributed to substantial reductions …

CSCI: Q2 2026 delivered higher sales, lower expenses, and a major turnaround in profitability

Estrella adds fourth site to EB103 lymphoma trial

Estrella Immunopharma Inc. has activated a fourth clinical site, University Hospitals Cleveland Medical Center, for its STARLIGHT-1 Phase I/II trial of EB103, an investigational T-cell therapy for B-cell non-Hodgkin's lymphoma. This expansion aims to evaluate the therapy's safety and efficacy, with data expected to …

Lyell Immunopharma VP Bulis sells $8,905 of common stock

Veronica Sanchez Bulis, VP at Lyell Immunopharma (NASDAQ:LYEL), sold 621 shares for $8,905 to cover tax obligations from vested restricted stock units. The company's stock has been volatile, down 53% YTD, but holds more cash than debt despite burning through cash quickly. Lyell also …

Zydus Deal Drops Mereo BioPharma A Lifeline For Rare Disease Candidate Alvelestat

Zydus's Sentynl and Mereo BioPharma have partnered to advance alvelestat, a rare disease drug. This collaboration provides a crucial boost for alvelestat's development. The article also mentions updates on other candidates, setrusumab and vantictumab, with the latter progressing to Phase II.

Lyell Immunopharma (LYEL) CEO sells shares to cover RSU tax withholding

Lyell Immunopharma's President and CEO, Lynn Seely, automatically sold 390 shares of common stock on August 10, 2026. This transaction was conducted to cover tax withholding obligations associated with vested restricted stock units. The shares were sold at a weighted average price of $14.34 …

Lyell Immunopharma (LYEL) VP auto-sells 621 shares to cover RSU taxes

Veronica Sanchez Bulis, VP and Corporate Controller at Lyell Immunopharma (LYEL), automatically sold 621 shares of common stock on August 10, 2026, at a weighted average price of $14.34 per share. This sale was conducted to cover tax withholding obligations associated with the settlement …

Vor Biopharma (NASDAQ:VOR) Posts Earnings Results

Vor Biopharma (NASDAQ:VOR) reported a Q2 loss of $0.80 per share, missing consensus estimates by $0.11. Shares closed down $0.39 at $22.98, though the stock remains well above its 52-week low. Analysts maintain a "Moderate Buy" rating with an average price target of $42.25, …

Mereo BioPharma Extends Cash Runway Into Late 2027 as Alvelestat Phase 3 Partnership Advances

Researcher looking through microscope ©gebakax The rare-disease biotech cut its quarterly net loss while a new Sentynl agreement could provide $40 million in upfront and R&D payments and funding for alvelestat's planned Phase 3 study. Key Investor Takeaways Mereo BioPharma (NASDAQ:MREO) extended its cash …

Vor Biopharma (VOR) Strengthens Cash Position Amid Unprofitable Operations

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

Aspire Biopharma Holdings, Inc. announced its successful participation in CPHI Frankfurt, engaging in strategic discussions with global pharmaceutical companies regarding its sublingual high-dose aspirin. The company conducted numerous meetings with major industry players to explore technical collaboration and licensing opportunities for its lead product …

Vor Biopharma Inc. reports results for the quarter ended June 30 - Earnings Summary

Vor Biopharma Inc. has reported its financial results for the quarter that ended on June 30. The article, sourced from Reuters and aggregated by TradingView, provides an earnings summary for the biopharmaceutical company. Readers need unlimited access to TradingView to read the full report.

Mereo BioPharma Group (NASDAQ:MREO) Issues Quarterly Earnings Results

Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma has announced the activation of University Hospitals Cleveland Medical Center as the fourth clinical site for its STARLIGHT-1 Phase I/II clinical trial. This trial is evaluating EB103, an ARTEMIS® T-cell therapy targeting CD19, for patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. …

Earnings Flash (VOR) Vor Biopharma Posts Q2 Net Loss $1.16 a Share, vs. FactSet Est of $0.70 Loss

Vor Biopharma (VOR) cuts losses as telitacicept trials advance and cash runway reaches 2029

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks

Theravance Biopharma TBPH reported second-quarter 2026 adjusted earnings of 19 cents per share, matching the Zacks Consensus Estimate. In the year-ago quarter, the company had incurred an adjusted loss of 8 cents per share. Total revenues in the quarter were $20.7 million, marginally beating …

Argent BioPharma (ASX:RGT) Expands CannEpil® Development Strategy with U.S. Veterinary Programme

Estrella adds fourth site to EB103 lymphoma trial By Investing.com

Estrella Immunopharma Inc. (NASDAQ:ESLA) has activated a fourth clinical site, University Hospitals Cleveland Medical Center, for its STARLIGHT-1 Phase I/II trial of EB103. This trial evaluates EB103, a CD19-redirected T-cell therapy, for patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. The company anticipates using …

Immunotech Biopharm Sets August Board Meeting to Approve Interim Results

Vor Biopharma Inc. 2Q 2026: Net loss $(62.8M), EPS $(1.16) — 10-Q Summary

Vor Biopharma Inc. reported a second-quarter 2026 net loss of $(62.8M) and diluted net loss per share of $(1.16), showing a significant improvement compared to the year-ago quarter. The company recorded no product revenue as it focuses on late-stage development programs, specifically advancing global …

HC Wainwright Estimates Immix Biopharma FY2027 Earnings

HC Wainwright forecasts Immix Biopharma (NASDAQ: IMMX) to report a loss of $0.20 per share for FY2027, maintaining a "Buy" rating and a $25 price target. This contrasts with the current consensus estimate of a $0.69 loss per share. The company recently reported a …

ConocoPhillips (NYSE:COP) Given New $161.00 Price Target at Susquehanna

Susquehanna has increased its price target for ConocoPhillips (NYSE:COP) to $161.00 from $155.00, maintaining a "positive" rating on the stock, implying a potential upside of 31.02%. This update follows ConocoPhillips' strong second-quarter results, where it surpassed earnings and revenue estimates and increased shareholder distributions. …